WO2004065583A3 - Gene expression markers for breast cancer prognosis - Google Patents

Gene expression markers for breast cancer prognosis Download PDF

Info

Publication number
WO2004065583A3
WO2004065583A3 PCT/US2004/000985 US2004000985W WO2004065583A3 WO 2004065583 A3 WO2004065583 A3 WO 2004065583A3 US 2004000985 W US2004000985 W US 2004000985W WO 2004065583 A3 WO2004065583 A3 WO 2004065583A3
Authority
WO
WIPO (PCT)
Prior art keywords
breast cancer
gene expression
cancer prognosis
expression markers
prognosis
Prior art date
Application number
PCT/US2004/000985
Other languages
French (fr)
Other versions
WO2004065583A2 (en
Inventor
Melody A Cobleigh
Steve Shak
Joffre B Baker
Maureen T Cronin
Original Assignee
Genomic Health Inc
Univ Rush Medical Center
Melody A Cobleigh
Steve Shak
Joffre B Baker
Maureen T Cronin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32771871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004065583(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genomic Health Inc, Univ Rush Medical Center, Melody A Cobleigh, Steve Shak, Joffre B Baker, Maureen T Cronin filed Critical Genomic Health Inc
Priority to EP15190640.1A priority Critical patent/EP3059322B1/en
Priority to EP04702177A priority patent/EP1587957B1/en
Priority to JP2006500964A priority patent/JP4723472B2/en
Priority to AT04702177T priority patent/ATE470723T1/en
Priority to DE602004027600T priority patent/DE602004027600D1/en
Priority to DK04702177.9T priority patent/DK1587957T3/en
Priority to AU2004205878A priority patent/AU2004205878B2/en
Priority to CA2513117A priority patent/CA2513117C/en
Publication of WO2004065583A2 publication Critical patent/WO2004065583A2/en
Publication of WO2004065583A3 publication Critical patent/WO2004065583A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
PCT/US2004/000985 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis WO2004065583A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP15190640.1A EP3059322B1 (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis
EP04702177A EP1587957B1 (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis
JP2006500964A JP4723472B2 (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis
AT04702177T ATE470723T1 (en) 2003-01-15 2004-01-14 GENE EXPRESSION MARKERS FOR BREAST CANCER PROGNOSIS
DE602004027600T DE602004027600D1 (en) 2003-01-15 2004-01-14 GENE EXPRESSION MARKERS FOR THE PROGNOSIS OF BREAST CANCER
DK04702177.9T DK1587957T3 (en) 2003-01-15 2004-01-14 Gene expression marker for breast cancer prognosis
AU2004205878A AU2004205878B2 (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis
CA2513117A CA2513117C (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44086103P 2003-01-15 2003-01-15
US60/440,861 2003-01-15

Publications (2)

Publication Number Publication Date
WO2004065583A2 WO2004065583A2 (en) 2004-08-05
WO2004065583A3 true WO2004065583A3 (en) 2005-03-03

Family

ID=32771871

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/000985 WO2004065583A2 (en) 2003-01-15 2004-01-14 Gene expression markers for breast cancer prognosis

Country Status (11)

Country Link
US (7) US20040231909A1 (en)
EP (4) EP2230318A1 (en)
JP (1) JP4723472B2 (en)
AT (1) ATE470723T1 (en)
AU (2) AU2004205878B2 (en)
CA (5) CA3013889A1 (en)
DE (1) DE602004027600D1 (en)
DK (3) DK2230319T3 (en)
ES (3) ES2725892T3 (en)
HK (1) HK1148783A1 (en)
WO (1) WO2004065583A2 (en)

Families Citing this family (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US20060062786A1 (en) * 2000-11-08 2006-03-23 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20090226429A1 (en) * 2001-05-25 2009-09-10 Human Genome Sciences, Inc. Antibodies That Immunospecifically Bind to TRAIL Receptors
US7361341B2 (en) * 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US20050214209A1 (en) * 2001-05-25 2005-09-29 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
US20030180296A1 (en) * 2001-12-20 2003-09-25 Theodora Salcedo Antibodies that immunospecifically bind to trail receptors
EP2258872B1 (en) * 2002-03-13 2013-08-14 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
CA3061769C (en) * 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) * 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
US20080131916A1 (en) * 2004-08-10 2008-06-05 Ring Brian Z Reagents and Methods For Use In Cancer Diagnosis, Classification and Therapy
US20100035240A1 (en) * 2004-08-10 2010-02-11 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
AU2005289756B2 (en) * 2004-09-22 2011-10-13 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
US8065093B2 (en) 2004-10-06 2011-11-22 Agency For Science, Technology, And Research Methods, systems, and compositions for classification, prognosis, and diagnosis of cancers
JP5020088B2 (en) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド Predicting response to chemotherapy using gene expression markers
DK1815014T3 (en) * 2004-11-05 2012-06-18 Genomic Health Inc Molecular indicators of breast cancer prognosis and prediction of treatment response
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
EP3698807A1 (en) 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006216732C1 (en) * 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
US20080275652A1 (en) * 2005-05-13 2008-11-06 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
ATE520979T1 (en) * 2005-08-24 2011-09-15 Bristol Myers Squibb Co BIOMARRKERS AND METHODS FOR DETERMINING SENSITIVITY TO MODULATORS OF THE EGF (EPIDERMAL GROWTH FACTOR) RECEPTOR
JP5129149B2 (en) 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating and diagnosing cancer
US7662580B2 (en) 2005-11-10 2010-02-16 Aurelium Biopharma Inc. Tissue diagnostics for breast cancer
TW200731980A (en) * 2005-12-29 2007-09-01 Alcon Mfg Ltd RNAi-mediated inhibition of HIF1A for treatment of ocular angiogenesis
WO2007123772A2 (en) * 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
ES2539042T3 (en) * 2006-06-02 2015-06-25 Glaxosmithkline Biologicals S.A. Identification procedure of whether a patient will respond to immunotherapy or not
WO2008063521A2 (en) * 2006-11-13 2008-05-29 The General Hospital Corporation Gene-based clinical scoring system
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
BRPI0809366B8 (en) 2007-03-28 2021-05-25 Harvard College substantially alpha-helical polypeptide, method for manufacturing same, amino acid and pharmaceutical composition
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
US9551033B2 (en) * 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
AU2008289148A1 (en) * 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
GB0720113D0 (en) * 2007-10-15 2007-11-28 Cambridge Cancer Diagnostics L Diagnostic, prognostic and predictive testing for cancer
WO2009067655A2 (en) * 2007-11-21 2009-05-28 University Of Florida Research Foundation, Inc. Methods of feature selection through local learning; breast and prostate cancer prognostic markers
EP2065475A1 (en) * 2007-11-30 2009-06-03 Siemens Healthcare Diagnostics GmbH Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor
US20110130296A1 (en) * 2008-03-14 2011-06-02 The Regents Of The University Of California Multi-gene classifiers and prognostic indicators for cancers
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
US10359425B2 (en) * 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100221752A2 (en) * 2008-10-06 2010-09-02 Somalogic, Inc. Ovarian Cancer Biomarkers and Uses Thereof
WO2010045234A1 (en) * 2008-10-14 2010-04-22 University Of Louisville Research Foundation, Inc. Methods of optimizing treatment of estrogen-receptor positive breast cancers
GB0821787D0 (en) * 2008-12-01 2009-01-07 Univ Ulster A genomic-based method of stratifying breast cancer patients
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
US20120225789A1 (en) * 2009-05-29 2012-09-06 Baylor College Of Medicine Dna repair or brca1-like gene signature
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for HER2 signaling in gastric cancer patients expressing HER2
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
EP2275569A1 (en) * 2009-07-17 2011-01-19 Centre Leon Berard ZNF217 a new prognostic and predictive biomarker of recurrent, invasive and metastatic phenotypes in cancer
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
DK2504451T3 (en) * 2009-11-23 2019-08-05 Genomic Health Inc Methods for predicting the clinical course of cancer
WO2011088137A2 (en) * 2010-01-12 2011-07-21 H. Lee Moffitt Cancer Center & Research Institute Bad pathway gene signature
US20130143753A1 (en) * 2010-03-01 2013-06-06 Adelbio Methods for predicting outcome of breast cancer, and/or risk of relapse, response or survival of a patient suffering therefrom
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
CA2804391A1 (en) 2010-07-07 2012-01-12 Myriad Genetics, Inc. Gene signatures for cancer prognosis
SG186953A1 (en) 2010-07-09 2013-02-28 Somalogic Inc Lung cancer biomarkers and uses thereof
CN106198980B (en) 2010-08-13 2018-09-07 私募蛋白质体公司 Cancer of pancreas biomarker and application thereof
US8859723B2 (en) 2010-08-13 2014-10-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc Gene signatures for cancer diagnosis and prognosis
US10011876B2 (en) 2010-11-23 2018-07-03 Krisani Biosciences Pvt. Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012109233A2 (en) * 2011-02-07 2012-08-16 Board Of Regents, The University Of Texas System Methods for predicting recurrence risk in breast cancer patients
CN108929375A (en) 2011-10-18 2018-12-04 爱勒让治疗公司 Peptidomimetic macrocyclic compound
WO2013070521A1 (en) * 2011-11-08 2013-05-16 Genomic Health, Inc. Method of predicting breast cancer prognosis
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2013170174A1 (en) * 2012-05-10 2013-11-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of diagnosing, treating and determining progression and survival of cancer cells using bcl-2 antagonist of cell death (bad) pathway gene signature
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
JP6526563B2 (en) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド Disubstituted amino acids and methods for their preparation and use
EP4190918A1 (en) 2012-11-16 2023-06-07 Myriad Genetics, Inc. Gene signatures for cancer prognosis
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
CA2896899A1 (en) 2013-01-18 2014-07-24 Ellis KLINE Selective glycosidase regimen for immune programming and treatment of cancer
WO2014124454A1 (en) 2013-02-11 2014-08-14 Katerina Gurova Use of facilitates chromatin transcription complex (fact) in cancer
CN103465779B (en) * 2013-09-17 2015-12-09 哈尔滨工程大学 Omnidirectional with double engines 4 wheel driven walking mechanism
CN103558382B (en) * 2013-10-28 2015-11-18 深圳市第二人民医院 The application of CCNE1 gene on detecting in bladder transitional cell carcinoma
CN103558383B (en) * 2013-10-28 2015-11-18 深圳市第二人民医院 The application of ALDH2 gene on detecting in bladder transitional cell carcinoma
KR20150088433A (en) 2014-01-24 2015-08-03 삼성전자주식회사 Biomarker TFF1 for predicting effect of a c-Met inhibitor
EP3623482A1 (en) 2014-05-13 2020-03-18 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10633710B2 (en) 2014-08-15 2020-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for characterizing cancer
SG10201902594QA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
US10905739B2 (en) 2014-09-24 2021-02-02 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
ES2833543T3 (en) 2014-10-24 2021-06-15 Koninklijke Philips Nv Evaluation of the activity of the TGF cell signaling pathway using mathematical models of target gene expression
CA2965217A1 (en) 2014-10-24 2016-04-28 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
AU2015334842B2 (en) 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
MX2017011834A (en) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
EP3073268A1 (en) * 2015-03-27 2016-09-28 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Biomarker panel for diagnosing cancer
CN108138237B (en) 2015-08-14 2022-04-05 皇家飞利浦有限公司 Assessment of NFkB cell signaling pathway activity using mathematical modeling of target gene expression
CN107058523A (en) * 2017-03-21 2017-08-18 温州迪安医学检验所有限公司 A kind of genetic test primer of breast carcinoma recurring risk assessment 21 and its application
EP3461915A1 (en) 2017-10-02 2019-04-03 Koninklijke Philips N.V. Assessment of jak-stat1/2 cellular signaling pathway activity using mathematical modelling of target gene expression
EP3502279A1 (en) 2017-12-20 2019-06-26 Koninklijke Philips N.V. Assessment of mapk-ap 1 cellular signaling pathway activity using mathematical modelling of target gene expression
CN110045120A (en) * 2018-01-15 2019-07-23 长庚医疗财团法人基隆长庚纪念医院 Detect detection kit and its application of the concentration of WISP1 in biological sample in preparation for breast cancer screening and detecting recurrence
WO2020013355A1 (en) * 2018-07-10 2020-01-16 서울대학교산학협력단 Composition for predicting prognosis of malignant phyllodes tumor and kit comprising same
EP4013896A4 (en) * 2019-08-12 2023-09-20 Baylor College of Medicine Proteogenomic methods for diagnosing cancer
CN113862363A (en) * 2021-10-27 2021-12-31 中山大学附属第一医院 Application of immune related gene in kit and system for breast cancer prognosis
CN114480650A (en) * 2022-02-08 2022-05-13 深圳市陆为生物技术有限公司 Marker and model for predicting three-negative breast cancer clinical prognosis recurrence risk

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001583A (en) * 1994-03-07 1999-12-14 New York University Medical Center Methods for disrupting GRB-7 complexes
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2001075160A1 (en) * 2000-03-31 2001-10-11 Vysis, Inc. Patient stratification for cancer therapy based on genomic dna microarray analysis
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
WO2002046467A2 (en) * 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues

Family Cites Families (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1252046A (en) 1982-11-04 1989-04-04 Martin J. Cline Methods for oncogenic detection
USRE35491E (en) 1982-11-04 1997-04-08 The Regents Of The University Of California Methods and compositions for detecting human tumors
US4699877A (en) 1982-11-04 1987-10-13 The Regents Of The University Of California Methods and compositions for detecting human tumors
US7838216B1 (en) 1986-03-05 2010-11-23 The United States Of America, As Represented By The Department Of Health And Human Services Human gene related to but distinct from EGF receptor gene
US5015568A (en) 1986-07-09 1991-05-14 The Wistar Institute Diagnostic methods for detecting lymphomas in humans
US5202429A (en) 1986-07-09 1993-04-13 The Wistar Institute DNA molecules having human BCL-2 gene sequences
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
US5922855A (en) * 1993-12-17 1999-07-13 Oregon Health Sciences University Mammalian DNA mismatch repair genes MLH1 and PMS1
US7625697B2 (en) * 1994-06-17 2009-12-01 The Board Of Trustees Of The Leland Stanford Junior University Methods for constructing subarrays and subarrays made thereby
US5858678A (en) 1994-08-02 1999-01-12 St. Louis University Apoptosis-regulating proteins
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US6218529B1 (en) * 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
US5882864A (en) 1995-07-31 1999-03-16 Urocor Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE69635740T2 (en) 1995-12-18 2006-09-14 Sugen, Inc., South San Francisco DIAGNOSIS AND TREATMENT OF AURA-1 AND / OR AUR-2 ASSOCIATED DISEASES
US6716575B2 (en) 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
US5670325A (en) 1996-08-14 1997-09-23 Exact Laboratories, Inc. Method for the detection of clonal populations of transformed cells in a genomically heterogeneous cellular sample
US5741650A (en) 1996-01-30 1998-04-21 Exact Laboratories, Inc. Methods for detecting colon cancer from stool samples
US5821082A (en) 1996-05-23 1998-10-13 St. Louis University Health Sciences Center Anti-proliferation domain of a human Bcl-2 and DNA encoding the same
US6143529A (en) 1996-08-14 2000-11-07 Exact Laboratories, Inc. Methods for improving sensitivity and specificity of screening assays
US5928870A (en) 1997-06-16 1999-07-27 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6146828A (en) 1996-08-14 2000-11-14 Exact Laboratories, Inc. Methods for detecting differences in RNA expression levels and uses therefor
US6100029A (en) 1996-08-14 2000-08-08 Exact Laboratories, Inc. Methods for the detection of chromosomal aberrations
US6020137A (en) 1996-08-14 2000-02-01 Exact Laboratories, Inc. Methods for the detection of loss of heterozygosity
US6203993B1 (en) 1996-08-14 2001-03-20 Exact Science Corp. Methods for the detection of nucleic acids
US5952178A (en) 1996-08-14 1999-09-14 Exact Laboratories Methods for disease diagnosis from stool samples
US5861278A (en) 1996-11-01 1999-01-19 Genetics Institute, Inc. HNF3δ compositions
KR100645448B1 (en) 1996-11-20 2006-11-13 예일 유니버시티 Survivin, a protein that inhibit cellular apoptosis, and its modulation
US5830665A (en) 1997-03-03 1998-11-03 Exact Laboratories, Inc. Contiguous genomic sequence scanning
US6033893A (en) 1997-06-26 2000-03-07 Incyte Pharmaceuticals, Inc. Human cathepsin
WO1999002714A1 (en) 1997-07-07 1999-01-21 Abbott Laboratories Reagents and methods useful for detecting diseases of the breast
WO1999020752A1 (en) * 1997-10-21 1999-04-29 The University Court Of The University Of Glasgow JMY, A CO-ACTIVATOR FOR p300/CBP, NUCLEIC ACID ENCODING JMY AND USES THEREOF
CA2318789C (en) * 1998-02-25 2011-05-10 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cellular arrays for rapid molecular profiling
US6020135A (en) 1998-03-27 2000-02-01 Affymetrix, Inc. P53-regulated genes
AU4158799A (en) 1998-06-06 1999-12-30 Genostic Pharma Limited Probes used for genetic filing
AU766544B2 (en) 1998-06-06 2003-10-16 Genostic Pharma Limited Probes used for genetic profiling
US6696558B2 (en) 1998-09-09 2004-02-24 The Burnham Institute Bag proteins and nucleic acid molecules encoding them
EP1115737A4 (en) 1998-09-23 2004-11-24 Cleveland Clinic Foundation Novel interferon stimulated and repressed genes
US6251601B1 (en) 1999-02-02 2001-06-26 Vysis, Inc. Simultaneous measurement of gene expression and genomic abnormalities using nucleic acid microarrays
AU3246200A (en) 1999-02-25 2000-09-14 Boris Bilynsky Nucleic acid molecules associated with melanoma and thyroid tumors
US20020039764A1 (en) 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
US6960439B2 (en) 1999-06-28 2005-11-01 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US6692916B2 (en) 1999-06-28 2004-02-17 Source Precision Medicine, Inc. Systems and methods for characterizing a biological condition or agent using precision gene expression profiles
US6326148B1 (en) 1999-07-12 2001-12-04 The Regents Of The University Of California Detection of copy number changes in colon cancer
US6710170B2 (en) 1999-09-10 2004-03-23 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
EP1218394A4 (en) 1999-10-06 2004-04-14 Univ California Differentially expressed genes associated with her-2/neu overexpression
EP2228446A1 (en) 1999-12-01 2010-09-15 Genentech, Inc. Secreted and transmembrane polypeptieds and nucleic acids encoding the same
US6750013B2 (en) 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
US6248535B1 (en) 1999-12-20 2001-06-19 University Of Southern California Method for isolation of RNA from formalin-fixed paraffin-embedded tissue specimens
WO2001051664A2 (en) * 2000-01-12 2001-07-19 Dana-Farber Cancer Institute, Inc. Method of detecting and characterizing a neoplasm
WO2001051661A2 (en) 2000-01-13 2001-07-19 Amsterdam Support Diagnostics B.V. A universal nucleic acid amplification system for nucleic acids in a sample
US6322986B1 (en) 2000-01-18 2001-11-27 Albany Medical College Method for colorectal cancer prognosis and treatment selection
EP1257664A4 (en) 2000-01-28 2006-04-05 Althea Technologies Inc Methods for analysis of gene expression
CA2395398A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU4592601A (en) 2000-03-21 2001-10-03 Millennium Predictive Medicine Novel genes, compositions, kits, and method for identification, assessment, prevention, and therapy of ovarian cancer
AU2001251086A1 (en) 2000-03-31 2001-10-15 Sir Mortimer B. Davis Jewish General Hospital Microchip arrays of regulatory genes
WO2002000677A1 (en) 2000-06-07 2002-01-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002008461A2 (en) 2000-07-21 2002-01-31 Global Genomics Ab A METHOD AND AN ALGORITHM FOR mRNA EXPRESSION ANALYSIS
AU2001277202A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ras/rerg protein and related reagents and methods of use thereof
US7118853B2 (en) 2000-07-26 2006-10-10 Applied Genomics, Inc. Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
AU2001278011A1 (en) 2000-07-26 2002-02-05 Applied Genomics, Inc. Bstp-ecg1 protein and related reagents and methods of use thereof
US7795232B1 (en) 2000-08-25 2010-09-14 Genta Incorporated Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6378397B1 (en) * 2000-10-25 2002-04-30 Jenn Jianq Co., Ltd. Differential gearing device
US6582919B2 (en) 2001-06-11 2003-06-24 Response Genetics, Inc. Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US6602670B2 (en) 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
AU2002255478A1 (en) 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
US7776518B2 (en) 2001-01-12 2010-08-17 Yale University Detection of survivin in the biological fluids of cancer patients
WO2002057787A2 (en) 2001-01-12 2002-07-25 Yale University Detection of survivin in the biological fluids of cancer patients
MXPA03006617A (en) 2001-01-24 2004-12-02 Protein Design Labs Inc Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer.
CN1554025A (en) 2001-03-12 2004-12-08 Īŵ���ɷ����޹�˾ Cell-based detection and differentiation of disease states
JP4222835B2 (en) * 2001-03-14 2009-02-12 株式会社Ｄｎａチップ研究所 Cancer prediction methods
US6655515B2 (en) * 2001-05-24 2003-12-02 Tecumseh Products Company Modular bi-directional overrunning wheel clutch
US7514209B2 (en) 2001-06-18 2009-04-07 Rosetta Inpharmatics Llc Diagnosis and prognosis of breast cancer patients
WO2003011897A1 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Modulation of heregulin and her3 interaction
US6898531B2 (en) * 2001-09-05 2005-05-24 Perlegen Sciences, Inc. Algorithms for selection of primer pairs
WO2003029273A2 (en) 2001-09-28 2003-04-10 Whitehead Institute For Biomedical Research Classification of lung carcinomas using gene expression analysis
US6964850B2 (en) 2001-11-09 2005-11-15 Source Precision Medicine, Inc. Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
EP1492871A2 (en) 2002-03-28 2005-01-05 QLT Inc. Cancer associated protein kinases and their uses
EP1365034A3 (en) 2002-05-21 2004-02-18 Bayer HealthCare AG Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
JP2006507841A (en) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド Functional and ultrafunctional siRNA
AU2004203749A1 (en) * 2003-01-06 2004-07-22 Wyeth Compositions and methods for diagnosing and treating colon cancers
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
PT1597391E (en) 2003-02-20 2008-12-19 Genomic Health Inc Use of intronic rna to measure gene expression
WO2004111603A2 (en) 2003-05-28 2004-12-23 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
CA3061769C (en) * 2003-06-24 2021-10-26 Genomic Health, Inc. Methods of predicting the likelihood of long-term survival of a human patient with node-negative, estrogen receptor (er) positive, invasive ductal breast cancer without the recurrence of breast cancer
WO2005008213A2 (en) 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
EP1737980A2 (en) 2004-04-09 2007-01-03 Fondazione IRCCS Istituto Nazionale dei Tumori Gene expression markers for predicting response to chemotherapy
DK1815014T3 (en) 2004-11-05 2012-06-18 Genomic Health Inc Molecular indicators of breast cancer prognosis and prediction of treatment response
JP5020088B2 (en) 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド Predicting response to chemotherapy using gene expression markers
CA2620936A1 (en) 2005-09-01 2007-03-08 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007123772A2 (en) 2006-03-31 2007-11-01 Genomic Health, Inc. Genes involved in estrogen metabolism
AU2008289148A1 (en) 2007-08-16 2009-02-26 Aventis Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
DK2294215T3 (en) 2008-05-12 2013-04-22 Genomic Health Inc Tests to predict cancer patients' response to various chemotherapeutic treatment options
KR101759175B1 (en) 2009-07-02 2017-07-18 바스프 에스이 Co-agglomerated latex polymer dispersions and methods of preparing and using same
DK2504451T3 (en) 2009-11-23 2019-08-05 Genomic Health Inc Methods for predicting the clinical course of cancer

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001583A (en) * 1994-03-07 1999-12-14 New York University Medical Center Methods for disrupting GRB-7 complexes
WO2000055173A1 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human breast and ovarian cancer associated gene sequences and polypeptides
WO2000055180A2 (en) * 1999-03-12 2000-09-21 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001075160A1 (en) * 2000-03-31 2001-10-11 Vysis, Inc. Patient stratification for cancer therapy based on genomic dna microarray analysis
WO2002010436A2 (en) * 2000-07-28 2002-02-07 The Brigham And Women's Hospital, Inc. Prognostic classification of breast cancer
WO2002046467A2 (en) * 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
WO2002059271A2 (en) * 2001-01-25 2002-08-01 Gene Logic, Inc. Gene expression profiles in breast tissue
WO2003078662A1 (en) * 2002-03-13 2003-09-25 Genomic Health Gene expression profiling in biopsied tumor tissues

Non-Patent Citations (15)

* Cited by examiner, † Cited by third party
Title
AHMAD A ET AL: "STROMELYSIN 3: AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSE-FREE SURVIVAL IN NODE-POSITIVE BREAST CANCER AND DEMONSTRATION OF NOVEL BREAST CARCINOMA CELL EXPRESSION", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 152, no. 3, March 1998 (1998-03-01), pages 721 - 728, XP001073488, ISSN: 0002-9440 *
BORRESEN-DALE A-L: "GENETIC PROFILING OF BREAST CANCER: FROM MOLECULAR PORTRAITS TO CLINICAL UTILITY", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, WICHTIG EDITORE, MILAN, IT, vol. 18, no. 1, 20 September 2002 (2002-09-20), pages 54 - 56, XP008036675, ISSN: 0393-6155 *
CHENARD M-P ET AL: "HIGH LEVELS OF STROMELYSIN-3 CORRELATE WITH POOR PROGNOSIS IN PATIENTS WITH BREAST CARCINOMA", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 69, no. 6, 1996, pages 448 - 451, XP008036913, ISSN: 0020-7136 *
ENGEL G ET AL: "CORRELATION BETWEEN STROMELYSIN-3 MRNA LEVEL AND OUTCOME OF HUMAN BREAST CANCER", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 58, no. 6, 1994, pages 830 - 835, XP008036912, ISSN: 0020-7136 *
FOROZAN FARAHNAZ ET AL: "Comparative genomic hybridization analysis of 38 breast cancer cell lines: A basis for interpreting complementary DNA microarray data", CANCER RESEARCH, vol. 60, no. 16, 15 August 2000 (2000-08-15), pages 4519 - 4525, XP002304931, ISSN: 0008-5472 *
GUERIN M ET AL: "STRUCTURE AND EXPRESSION OF C-ERBB-2 AND EGF RECEPTOR GENES IN INFLAMMATORY AND NON-INFLAMMATORY BREAST CANCER: PROGNOSTIC SIGNIFICANCE", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 43, 1989, pages 201 - 208, XP002935671, ISSN: 0020-7136 *
LEEK R D ET AL: "ASSOCIATION OF MACROPHAGE INFILTRATION WITH ANGIOGENESIS AND PROGNOSIS IN INVASIVE BREAST CARCINOMA", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, 15 October 1996 (1996-10-15), pages 4625 - 4629, XP002056968, ISSN: 0008-5472 *
MURRAY P A ET AL: "The prognostic significance of transforming growth factors in human breast cancer", BRITISH JOURNAL OF CANCER, vol. 67, no. 6, 1993, pages 1408 - 1412, XP008031811, ISSN: 0007-0920 *
RASCHELLA GIUSEPPE ET AL: "Expression of B-myb in neuroblastoma tumors is a poor prognostic factor independent from MYCN amplification", CANCER RESEARCH, vol. 59, no. 14, 15 July 1999 (1999-07-15), pages 3365 - 3368, XP002304932, ISSN: 0008-5472 *
SAMUELS-LEV YARDENA ET AL: "ASPP proteins specifically stimulate the apoptotic function of p53", MOLECULAR CELL, vol. 8, no. 4, October 2001 (2001-10-01), pages 781 - 794, XP002202189, ISSN: 1097-2765 *
SCHORR K ET AL: "BCL-2 GENE FAMILY AND RELATED PROTEINS IN MAMMARY GLAND INVOLUTION AND BREAST CANCER", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, PLENUM PRESS, NEW YORK, NY,, US, vol. 4, no. 2, April 1999 (1999-04-01), pages 153 - 164, XP000973885, ISSN: 1083-3021 *
SENS MARY ANN ET AL: "Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis", AMERICAN JOURNAL OF PATHOLOGY, vol. 159, no. 1, July 2001 (2001-07-01), pages 21 - 26, XP002285193, ISSN: 0002-9440 *
SGROI D C ET AL: "IN VIVO GENE EXPRESSION PROFILE ANALYSIS OF HUMAN BREAST CANCER PROGRESSION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5656 - 5661, XP000994514, ISSN: 0008-5472 *
UENO T ET AL: "Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. AUG 2000, vol. 6, no. 8, August 2000 (2000-08-01), pages 3282 - 3289, XP002304930, ISSN: 1078-0432 *
VEER VAN 'T L J ET AL: "Gene expression profiling predicts clinical outcome of breast cancer", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 415, no. 6871, 31 January 2002 (2002-01-31), pages 530 - 536, XP002259781, ISSN: 0028-0836 *

Also Published As

Publication number Publication date
HK1148783A1 (en) 2011-09-16
CA3013889A1 (en) 2004-08-05
EP2230318A1 (en) 2010-09-22
US20140287421A1 (en) 2014-09-25
US20040231909A1 (en) 2004-11-25
AU2009238287B2 (en) 2012-06-28
US11220715B2 (en) 2022-01-11
AU2009238287A1 (en) 2009-12-03
CA2513117A1 (en) 2004-08-05
JP2006516897A (en) 2006-07-13
EP3059322B1 (en) 2019-04-10
WO2004065583A2 (en) 2004-08-05
AU2004205878A8 (en) 2004-08-05
CA2513117C (en) 2014-02-25
EP1587957B1 (en) 2010-06-09
ATE470723T1 (en) 2010-06-15
AU2004205878A1 (en) 2004-08-05
EP1587957A2 (en) 2005-10-26
AU2004205878B2 (en) 2009-08-27
US20180230548A1 (en) 2018-08-16
US9944990B2 (en) 2018-04-17
CA2829476C (en) 2018-07-10
US8741605B2 (en) 2014-06-03
EP2230319A2 (en) 2010-09-22
CA2829477A1 (en) 2004-08-05
DK1587957T3 (en) 2010-09-27
EP3059322A1 (en) 2016-08-24
US20110312532A1 (en) 2011-12-22
US8034565B2 (en) 2011-10-11
CA2829477C (en) 2018-07-10
DK2230319T3 (en) 2016-01-25
US20120225433A1 (en) 2012-09-06
DK3059322T3 (en) 2019-05-06
ES2561179T3 (en) 2016-02-24
ES2346967T3 (en) 2010-10-22
EP2230319A3 (en) 2011-01-12
US20040209290A1 (en) 2004-10-21
CA2829476A1 (en) 2004-08-05
JP4723472B2 (en) 2011-07-13
CA2829472A1 (en) 2004-08-05
DE602004027600D1 (en) 2010-07-22
EP2230319B1 (en) 2015-10-21
US8206919B2 (en) 2012-06-26
US20100222229A1 (en) 2010-09-02
CA2829472C (en) 2018-08-14
US7569345B2 (en) 2009-08-04
ES2725892T3 (en) 2019-09-30

Similar Documents

Publication Publication Date Title
WO2004065583A3 (en) Gene expression markers for breast cancer prognosis
WO2005039382A3 (en) Prediction of likelihood of cancer recurrence
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
WO2007016548A3 (en) Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
WO2007109236A3 (en) Microrna fingerprints during human megakaryocytopoiesis
WO2004111273A3 (en) Gene expression markers for response to egfr inhibitor drugs
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
HK1108284A1 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
EP1590433A4 (en) Diagnosis and prognosis of breast cancer patients
WO2006037462A3 (en) Cancer markers
AU2003225093A8 (en) Soluble mic polypeptides as markers for diagnosis, prognosis and treatment of cancer and autoimmune diseases or conditions
AU2003300368A1 (en) Methods and compositions for the diagnosis, prognosis, and treatment of cancer
EP1522594A3 (en) Methods and kits for investigating cancer
EP1742654A4 (en) Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer
WO2005001046A3 (en) Methods for predicting the course of a malignant disease
AU2003217397A1 (en) Claudins, markers for diagnosis, prognosis and therapy of breast, bone, brain cancer
WO2006015191A3 (en) Multicyclic lonidamine analogs
GB0417740D0 (en) Methods and kit for the prognosis of breast cancer
WO2005106043A3 (en) Breast cancer gene expression biomarkers
AU2003218208A1 (en) Methods for diagnosis and prognosis of cancer
WO2005056043A3 (en) Use of enzymatic inhibitors of h-prune for the prevention and treatment of the metastases of tumours overexpressing h-prune
WO2004096021A3 (en) Global analysis of transposable elements as molecular markers of cancer
AU2003298609A1 (en) Method and cloning vector for preparing multiple-gene diagnostic probes for the assessment of multiple markers for breast cancer prognosis
AU2003248889A1 (en) Multiple gene diagnostic probes and assay kits and method for the assessment of multiple markers for breast cancer prognosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2513117

Country of ref document: CA

Ref document number: 2004205878

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006500964

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004702177

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004205878

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004702177

Country of ref document: EP